JP6280499B2 - Ｆｃ融合タンパク質の精製方法 - Google Patents

Ｆｃ融合タンパク質の精製方法 Download PDF

Info

Publication number
JP6280499B2
JP6280499B2 JP2014519246A JP2014519246A JP6280499B2 JP 6280499 B2 JP6280499 B2 JP 6280499B2 JP 2014519246 A JP2014519246 A JP 2014519246A JP 2014519246 A JP2014519246 A JP 2014519246A JP 6280499 B2 JP6280499 B2 JP 6280499B2
Authority
JP
Japan
Prior art keywords
protein
chromatography
tnfr
elution
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014519246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520814A5 (enExample
JP2014520814A (ja
Inventor
イケチユキユ，イジェオマ・シンシア
ンテイ−ギヤバアー，ジヨセフ
ペトロフ，マシユー
リー，クリステイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2014520814A publication Critical patent/JP2014520814A/ja
Publication of JP2014520814A5 publication Critical patent/JP2014520814A5/ja
Application granted granted Critical
Publication of JP6280499B2 publication Critical patent/JP6280499B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
JP2014519246A 2011-07-08 2012-07-03 Ｆｃ融合タンパク質の精製方法 Expired - Fee Related JP6280499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505710P 2011-07-08 2011-07-08
US61/505,710 2011-07-08
PCT/US2012/045339 WO2013009526A1 (en) 2011-07-08 2012-07-03 Method for purifying fc-fusion protein

Publications (3)

Publication Number Publication Date
JP2014520814A JP2014520814A (ja) 2014-08-25
JP2014520814A5 JP2014520814A5 (enExample) 2015-07-30
JP6280499B2 true JP6280499B2 (ja) 2018-02-14

Family

ID=47506409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519246A Expired - Fee Related JP6280499B2 (ja) 2011-07-08 2012-07-03 Ｆｃ融合タンパク質の精製方法

Country Status (10)

Country Link
US (1) US9556258B2 (enExample)
EP (1) EP2729482B1 (enExample)
JP (1) JP6280499B2 (enExample)
KR (1) KR20140043934A (enExample)
CN (1) CN103814044A (enExample)
AU (2) AU2012282960A1 (enExample)
BR (1) BR112014000352A2 (enExample)
CA (1) CA2840951A1 (enExample)
DK (1) DK2729482T3 (enExample)
WO (1) WO2013009526A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
AU2013315750B9 (en) * 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
AU2014240596B2 (en) 2013-03-14 2018-09-27 Amgen Inc. Removal of leaked affinity purification ligand
SG11201507875RA (en) * 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
EP3102589A1 (en) * 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3137209B1 (en) 2014-05-02 2022-10-05 W.R. Grace & CO. - CONN. Functionalized support material and methods of making and using functionalized support material
JP6661547B2 (ja) 2014-05-13 2020-03-11 アムジエン・インコーポレーテツド フィルタ及び濾過プロセスで用いるためのプロセス制御システム及び方法
WO2015189832A1 (en) 2014-06-13 2015-12-17 Lupin Limited Process for the purification of tnfr:fc fusion protein
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
US11053504B2 (en) * 2014-10-24 2021-07-06 The University Of Chicago Heat-inducible self-assembling protein domains
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10988527B2 (en) 2014-12-31 2021-04-27 Lg Chem, Ltd. Method for preparing TNFR-Fc fusion protein containing target content of impurities
SG10201911134QA (en) * 2015-06-05 2020-01-30 Grace W R & Co Adsorbent bioprocessing clarification agents and methods of making and using the same
AU2016329001A1 (en) 2015-09-22 2018-03-29 Genentech, Inc. Expression of Fc-containing proteins
US20170101435A1 (en) * 2015-10-13 2017-04-13 Therapeutic Proteins International, LLC Harvesting and perfusion apparatus
WO2017087882A1 (en) 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
KR102435801B1 (ko) * 2016-07-22 2022-08-25 암젠 인크 Fc-함유 단백질의 정제 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
US12233356B2 (en) * 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN112574321B (zh) * 2020-12-30 2023-10-20 上海赛金生物医药有限公司 一种捕获单克隆抗体-肿瘤坏死因子融合蛋白的亲和纯化方法
US20240148866A1 (en) * 2021-02-11 2024-05-09 Denali Therapeutics Inc. Anti-transferrin receptor fusion proteins and methods of use thereof
AU2022358612A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
EP4408879A4 (en) * 2021-09-28 2025-08-27 Kashiv Biosciences Llc IMPROVED PROCESS FOR PURIFYING FUSION PROTEIN
CN114891061A (zh) * 2022-04-25 2022-08-12 杭州艾策生物技术有限公司 一种糖基化重组蛋白的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031806A2 (en) 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc RECEPTORS AND POLYPEPTIDES
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
PL374311A1 (en) * 2001-12-21 2005-10-03 Immunex Corporation Methods for purifying protein
WO2004008100A2 (en) * 2002-07-15 2004-01-22 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
DE602004026343D1 (de) * 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
CA2562766A1 (en) * 2004-04-14 2005-10-27 F. Hoffmann-La Roche Ag Purified interleukin-15/fc fusion protein and preparation thereof
BRPI0716139A2 (pt) * 2006-08-28 2013-09-17 Ares Trading Sa processo para purificaÇço de proteÍnas de fusço fc
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
ES2391931T3 (es) 2008-09-15 2012-12-03 Emd Millipore Corporation Procedimientos para cuantificar la filtración de proteína desde resinas de cromatografía de afinidad basada en proteína
WO2010127069A1 (en) 2009-04-29 2010-11-04 Schering Corporation Antibody purification
ES2817802T3 (es) * 2009-08-07 2021-04-08 Emd Millipore Corp Métodos para purificar una proteína objetivo de una o más impurezas en una muestra
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production

Also Published As

Publication number Publication date
AU2012282960A1 (en) 2014-01-16
DK2729482T3 (en) 2018-05-07
US20140187751A1 (en) 2014-07-03
EP2729482A1 (en) 2014-05-14
KR20140043934A (ko) 2014-04-11
AU2017204893A1 (en) 2017-08-03
CA2840951A1 (en) 2013-01-17
BR112014000352A2 (pt) 2017-02-14
US9556258B2 (en) 2017-01-31
WO2013009526A1 (en) 2013-01-17
EP2729482A4 (en) 2015-02-25
JP2014520814A (ja) 2014-08-25
CN103814044A (zh) 2014-05-21
EP2729482B1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
US9556258B2 (en) Purification of fusion proteins
US11459374B2 (en) Anti-VEGF protein compositions and methods for producing the same
US20220289832A1 (en) Protein purification
US20140288278A1 (en) Chromatography process for resolving heterogeneous antibody aggregates
TW201444863A (zh) 增加蛋白質之焦－麩胺酸形成的方法
US20240343758A1 (en) Process for purification of protein
CA3214610A1 (en) Purification of antibodies by mixed mode chromatography
HK40096315A (zh) 通过混合模式色谱纯化抗体
Grzeskowiak 2-D DIGE to facilitate downstream process development for recombinant therapeutic antibodies
HK1184467A (en) Protein purification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180119

R150 Certificate of patent or registration of utility model

Ref document number: 6280499

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees